← Back to Flunitrazolam

Flunitrazolam Stats & Data

Depressant Research-chemical Benzodiazepine

Fln Fntz Flunazolam

NPS DataHub

MW337.31

FormulaC17H12FN5O2

IUPAC1-methyl-8-nitro-6-(2-fluorophenyl)-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine

SMILESO=N(=O)c1ccc2n3c(C)nnc3CN=C(c3ccccc3F)c2c1

InChIKeyRDLAGIOILLWVTM-UHFFFAOYSA-N

Benzodiazepines; 2020/3. Benzodiazepine; 2021/3. Benzodiazepine; 2022/3. Benzodiazepine

Chemical Class Benzodiazepine

Psychoactive Class Depressant

Half-Life Unknown in humans; user reports suggest a several‑hour main effect with possible next‑day residual sedation—treat as potentially long‑lasting compared with short‑acting hypnotics.

Receptor Profile

Receptor Actions

Modulators

GABA-A receptor positive allosteric modulator (benzodiazepine site)

History & Culture

Flunitrazolam is a novel designer benzodiazepine with no documented history prior to its emergence on the online research chemical market. Unlike many benzodiazepines which were first developed by pharmaceutical companies and later diverted to recreational use, flunitrazolam appears to have been synthesized specifically for the grey market without any preceding scientific or patent literature. The compound was first definitively identified in October 2016, when an analytical laboratory in Germany detected and reported it to the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) Early Warning System. It subsequently became available for purchase through online vendors, typically sold as pressed pellets alongside other novel triazolobenzodiazepines such as clonazolam and flubromazolam. As the triazole analogue of flunitrazepam (marketed pharmaceutically as Rohypnol), flunitrazolam represents part of a broader trend of designer benzodiazepines appearing on research chemical markets during the mid-2010s, with vendors systematically exploring structural modifications to existing benzodiazepine scaffolds.

Effect Profile

Curated + 4 Reports

Benzodiazepine 6.9

Strong anxiolysis and cognitive impairment with moderate sedation and euphoria

Anxiolysis×3

Sedation / Relaxation×2

Motor / Cognitive Impairment×1

Euphoria / Mood Lift×1

Based on reports from:

Erowid Experience Reports PsychonautWiki Flunitrazolam

Tolerance & Pharmacokinetics

drugs.wiki

Half-Life

Unknown in humans; user reports suggest a several‑hour main effect with possible next‑day residual sedation—treat as potentially long‑lasting compared with short‑acting hypnotics.

Addiction Potential

High. Potent triazolobenzodiazepines are strongly habit-forming with rapid tolerance development and severe, potentially dangerous withdrawal if dependent.

Tolerance Decay

Full tolerance 3d Half tolerance 7d Baseline ~28d

Tolerance to sedation/anxiolysis can build within several consecutive days of use and declines over 1–4 weeks of abstinence; estimates are generalized from benzodiazepine class guidance and HR resources rather than drug‑specific studies.

Cross-Tolerances

Other benzodiazepines

80% ●○○

Thienodiazepines (e.g., etizolam)

70% ●○○

Non‑benzodiazepine Z‑drugs

50% ●○○

Experience Report Analysis

Erowid

4 Reports

2016–2020 Date Range

4 With Age Data

3 Effects Detected

Demographics

Gender Distribution

Age Distribution

Reports Over Time

Effect Analysis

Erowid

Effects aggregated from 4 experience reports (4 Erowid)

4 Reports

3 Effects Detected

2 Positive

1 Adverse

0 Neutral

Effect Sentiment Distribution

Confidence Distribution

Positive Effects 2

Sedation 75.0% 70%

Anxiety Suppression 75.0% 70%

Adverse Effects 1

Psychosis 75.0% 70%

Real-World Dose Distribution

62K Doses

From 4 individual dose entries

Read full reports on Erowid →

Legal Status

Country	Status	Notes
Switzerland	Legal	Legal as of September 2021. Not a scheduled or controlled substance under Swiss narcotics law.

Harm Reduction

drugs.wiki

• Microgram potency: active oral doses commonly fall between 0.1–0.25 mg. Equipment or cutting errors have caused blackouts and unintentional overdoses; volumetric dosing and a calibrated scale (0.001 g readability) are harm‑reduction best practices.

• Strong amnesia/blackout risk: many reports describe anterograde amnesia with disinhibition. Avoid redosing during the first 2 hours; set timers and keep a written log of each dose to reduce binge/blackout risk.

• Combining with depressants greatly increases overdose risk via additive respiratory/CNS depression. The highest‑risk mixes are with opioids, alcohol, GHB/GBL, gabapentinoids, and dissociatives.

• Counterfeit/unknown tablets are common: many “benzo” pills contain unexpected substances (other potent benzos, antihistamines, or even opioids). Whenever possible, use a trusted drug‑checking service; assume mislabeling risk in unregulated markets.

• Next‑day impairment is possible even at low doses; do not drive or operate machinery until fully sober. Residual effects may last into the next day.

• Dependence and withdrawal: benzodiazepine withdrawal can be severe and potentially life‑threatening (seizures). Do not stop abruptly after repeated use; medical supervision and gradual tapering are advised.

• Avoid injecting or snorting: most benzos and tablet fillers have poor aqueous solubility; crushing tablets for solutions risks vein damage and emboli.

• Overdose management: flumazenil is a hospital‑use antidote; unsupervised use can precipitate acute withdrawal and seizures in dependent polydrug users—seek emergency care instead of attempting layperson reversal.

• High variability across batches/vendors has been noted for designer benzos; treat each new batch cautiously and test a low dose first (“allergy test”), waiting full onset.

• Keep access to additional doses limited (pre‑measured only), secure sharp objects/valuables, and avoid online shopping or driving while under the influence to mitigate blackout‑related harms. (Harm‑reduction practice based on common benzo blackout behaviors described in user reports.)